本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
HONG KONG, Dec. 12, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody. The study will compare cadonilimab plus chemotherapy against chemotherapy with or without nivolumab as first-line treatment for HER2-negative, unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma. This is the second international registrational study for cadonilimab, following the ongoing trial in immunotherapy-resistant hepatocellular carcinoma. COMPASSION-37 represents a pivotal advancement in cadonilimab's global development and a concrete step in Akeso's worldwide strategy, reinforcing its leadership in next-generation immuno-oncology. The company remains committed to its dual-track approach of proprietary development and strategic collaboration, leveraging global resources to accelerate cadonilimab's international availability and expand accessible treatment options for patients worldwide. Chemotherapy with or without PD-1 inhibitors, such as nivolumab, represents the international standard of care for advanced gastric cancer. However, the disease exhibits significant heterogeneity. While PD-1 treatment in combination with chemotherapy remains an effective treatment in many gastric cancer patients with high PD-L1 expression (CPS >5), its efficacy is markedly limited in gastric cancer patients with low PD-L1 expression (CPS <5) or negative PD-L1 expression (CPS <1). These low and negative PD-L1 patients constitute well more than half of the total gastric cancer patient population. In 2024, the FDA narrowed the indication for all approved PD-1 inhibitors in the first-line treatment of advanced gastric cancer, restricting their use to PD-L1-positive patients. Authoritative guidelines, including those from the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO), also prioritize recommending nivolumab-based regimens for patients with PD-L1 CPS ≥5. This underscores that treating advanced gastric cancer in PD-L1 low-expressing and negative patients has become a globally recognized clinical challenge. In 2024, based on the COMPASSION-15 study results, cadonilimab in combination with chemotherapy was approved in China for the first-line treatment of gastric cancer, demonstrating benefit across all patient populations, including both PD-L1 positive and negative subgroups. COMPASSION-15 is the only global Phase III clinical study in first-line advanced gastric cancer to have demonstrated survival benefit across all patient populations, irrespective of PD-L1 expression status. In this trial, patients with low PD-L1 expression and those who were PD-L1-negative accounted for as high as 49.8% and 23% of the enrolled population, respectively, significantly exceeding proportions observed in historical studies of its kind. The robust representation of low and negative PD-L1 patients in the study and the effective treatment of these patients validates cadonilimab's broad-spectrum antitumor efficacy beyond PD-L1 dependency in gastric cancer. Long-term follow-up data showed that cadonilimab plus chemotherapy significantly reduced the risk of death by 39% in the overall population compared to the control group (OS HR 0.61), regardless of PD-L1 status. In the PD-L1 CPS ≥5 subgroup, the reduction in mortality risk reached 51% (OS HR 0.49). Importantly, even among patients with low PD-L1 expression (CPS <5), a statistically significant 24% reduction in mortality risk was maintained (OS HR 0.76). These results were presented as an oral report at ESMO 2025. Earlier interim analysis data from the COMPASSION-15 study had been released as a prominent oral presentation at AACR 2024, with the full manuscript subsequently published in the Nature Medicine. These results highlight cadonilimab's potential to elevate the current standard of tumor immunotherapy and address clinical challenges unmet by single-target agents. Forward-Looking Statement of Akeso, Inc. This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law. About Akeso Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 26 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise. For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin.
Securely connecting AI agents across multiple companies for rapid response to changing circumstances KAWASAKI, Japan, Dec. 1, 2025 /PRNewswire/ -- Fujitsu Limited today announced the development of a multi-AI agent collaboration technology that enables secure collaboration and swift response to changing circumstances among AI agents from different companies and vendors within a supply chain. Leveraging this technology, Fujitsu will start field trials in January 2026 to optimize the supply chain of Rohto Pharmaceutical Co., Ltd. in collaboration with the Institute of Science Tokyo (Science Tokyo). This innovation not only streamlines daily supply chain operations but also facilitates rapid recovery during emergencies like sudden demand shifts or disasters. In addition, Fujitsu will contribute to the new industry promotion activities of the Council on Competitiveness-Nippon (COCN) to realize AI spaces that enable secure data and AI collaboration across different companies, aiming to strengthen the competitiveness of Japanese industry through agentic AI. Fujitsu will continue to advance demonstration and technological enhancement with Science Tokyo and Rohto Pharmaceutical, aiming for expansion into diverse industries, including manufacturing. Fujitsu will also develop technology for broader and more complex supply chains, targeting provision through its Uvance business model's Dynamic Supply Chain services by the end of fiscal 2026. This will bring a new perspective to corporate supply chain strategies, enhancing resilience, and enabling sustainable business operations. Under its Uvance business model, Fujitsu will leverage the technology developed in these trials to realize secure data collaboration through AI agent cooperation across borders and industries. This will drive resilient supply chains and sustainable industrial growth, ensuring reliability and governance in multi-vendor environments. Katsuki Fujisawa, Professor, Digital Twin Research Unit, Institute of Integrated Research, and Department of Mathematical and Computing Science, School of Computing, Science Tokyo, comments: "Science Tokyo is actively promoting Cyber-Physical Systems (CPS) research and working to improve efficiency across the entire industrial value chain. Moving forward, by collaborating with Fujitsu's agentic AI technology to optimize the entire supply chain, we aim to contribute to the advancement of industry and the resolution of societal challenges." For full release click here
FRANKFURT, Germany, Nov. 20, 2025 /PRNewswire/ -- Anycubic returned to Formnext 2025 with a highly anticipated trio of new products, presenting a clear vision for the next generation of desktop manufacturing. At booth 12.1-F129, the company introduced two advanced FDM systems—Kobra S1 Max and Kobra X—alongside its new resin flagship, the Photon P1, marking a significant upgrade in speed, stability, and material capability. "The boundary between hobby tools and production tools is disappearing. What creators need now is desktop equipment that behaves like factory-grade machinery—steady, predictable, and material-ready. This is exactly the direction this year's lineup takes," noted James Ouyang, Anycubic's CTO. Anycubic Introduces Three Breakthrough Products at Formnext 2025 Kobra S1 Max: Large-Format CoreXY for Engineering-Grade Output The Kobra S1 Max stands out as Anycubic's new large-format CoreXY platform, designed for users who demand production-level stability and material versatility. Equipped with a 350 × 350 × 350 mm³ build volume, a 65°C actively heated chamber, 350°C hotend, and 120°C heated bed, it supports engineering materials including PC, PA, ABS, and carbon-fiber composites. The system debuts the upgraded ACE 2 Pro, driven by four independent brushless motors, dramatically reducing color-change time while improving stability and noise control. Combined with hardened-steel extrusion components and LeviQ 3.0 auto-leveling, the S1 Max is built for creators producing functional, durable parts at scale. Kobra X: Second-Generation Multi-Color & Multi-Material System The Kobra X refines Anycubic's single-nozzle multi-color technology with a second-generation architecture optimized for cleaner transitions and reduced material waste. Its new ACE GEN2 shortens the purging distance from 160 mm to just 30 mm, reducing time and filament consumption by nearly half. Standard support includes 4-color printing (expandable up to 19 colors) and stable mixing of PLA + TPU or PLA + PVA, improved extrusion pressure control, and high-speed motion performance reaching 600 mm/s. Photon P1: A Prosumer Resin Flagship with Industrial Precision Making its first public debut, the Photon P1 introduces industrial-grade components to the desktop resin category. The machine supports resins up to 8000 cps, features a dual-platform and dual-vat system for true two-material printing, and incorporates a Wave Release Film + NFEP dual-layer separation system that reduces peel force by 60%. With ±0.01 mm Z-axis repeatability, a high-flatness steel build plate, and the LightTurbo 4.0 optical engine delivering 92% light uniformity, the P1 is built for both precision prototyping and small-batch production. "A resin machine designed not just for models, but for real parts—functional, repeatable, and ready for small-batch production," said James. Shaping the Next Standard of Desktop Manufacturing Anycubic highlighted three industry trends driving its 2025 lineup: higher automation, stronger material adaptability, and the shift from hobby-grade tools toward production-ready desktop systems. James summarized this direction clearly: "Our goal is simple: bring factory-level capability to a desktop footprint, and make it accessible to the global maker and engineering community." Together, the Kobra S1 Max, Kobra X, and Photon P1 form a cohesive ecosystem designed for creators, engineers, and small-scale manufacturers seeking reliable, high-performance desktop fabrication.
SHANGHAI, CHINA - Media OutReach Newswire - 17 November 2025 – On April 21 to 24, 2026, the industry's acclaimed trade fair - CHINAPLAS 2026 will take place at National Exhibition and Convention Center in Hongqiao, Shanghai, PR China. As one of the global leading plastics and rubber exhibitions, this edition is expected to span over 390,000 square meters across 16 halls, bringing together over 4,600 exhibitors worldwide to showcase breakthroughs in new materials, intelligent innovations and green transformations. The show aims to strengthen the industries' upgrade towards high-end, intelligent, and green development, as well as transition from "Made in China" to "Innovated in China". Evolving with Time: Empowering New Quality Productive Forces from 3 Core Dimensions Amidst accelerated revolution in technology, energy and industries, the new quality productive forces, particularly in innovation and green low-carbon, have become crucial drivers of high-quality development. CHINAPLAS 2026 captures these trends by gathering top global exhibitors to present cutting-edge products and solutions, constructing an ecosystem of industrial innovation. Breakthroughs in New Materials: Meeting Downstream Industries' Progression Needs. With rapid growth in downstream sectors including new energy vehicles, low-altitude economy, aerospace, rail transportation, humanoid robotics, wind power and photovoltaics, CHINAPLAS 2026 will focus on "driving application upgrades with material innovation" and feature renewal of advanced frontier materials. Diversified modified plastics and special thermoplastic elastomers enhance strength and electrical conductivity of plastics and rubber products, making them suitable for new energy vehicles' batteries and aerospace seals; high-performance engineering plastics offer resistance to high and low-temperatures plus corrosion for high-end equipment; light and durable thermoplastic composites materials have become critical supporting materials for low-altitude economy and humanoid robot industries. Intelligent Evolution: Opening the Door to "Smart Manufacturing Era". Artificial intelligence and automation technologies are restructuring manufacturing logic of plastics and rubber industries, accelerating their transition into the "smart manufacturing era". At CHINAPLAS 2026, comprehensive intelligent manufacturing solutions reshaping entire production chain will be showcased-from automated injection molding, extrusion and blow molding production lines, to industrial IoT-driven digital management systems, intelligent inspection and quality control platforms. These advancements enable enterprises to improve production efficiency and optimize labor costs, further driving manufacturing industry's leap from automation to intelligence. Green Transformation: Decoding the solutions to the "Dual Carbon" goals. In reaching the national carbon peaking and neutrality "Dual Carbon" goals in China, green and low-carbon solutions have become crucial factors for high-quality growth. They have also laid the pivotal path for sustainable development of plastics and rubber industries. CHINAPLAS 2026 will introduce innovative environmental and carbon reduction technologies and solutions, providing clear directions for enterprises to achieve green transformation. Efficacious boost with carbon reduction: additives produced with carbon capture technology can reduce carbon emissions during plastic production process; Recycling: technologies in recycling oil and repurposing volatile organic compounds convert waste into valuable resources, fostering achievement of circular economy; Materials advancement: with key roles in enhancing the functionality of recycled plastics and bioplastics, adoption of bio-based/bio-degradable/eco-compatible coupling and toughening agents into productions empower enterprises to expand their business into the green product markets, achieving operational transformation to streamline their compliance with environmental standards. Elevation in Scale and Quality, New Innovative Forces Ignite Inspiration Sparks CHINAPLAS 2026 not only achieves advancement in quantity, but also quality. As of now, booths reserved has far exceeded forecast, further expanding the exhibition area from 2024 edition in Shanghai to a new record of over 390,000 square meters. The organizer has enriched exhibitor spectrum by encompassing more pioneering technology companies and innovative plastics and rubber suppliers, delivering a unique experience to all visitors. Two notable highlights of the trade fair are diversity and quality of exhibitors. Renowned plastics and rubber enterprises will gather to showcase cutting-edge technologies and exchange industry visions, connecting Chinese companies to international standards. With emergence of power in China's innovation, more than 1,400 "Shining Niche" companies (enterprises recognized by the Chinese government in fields including economic benefits, specialization and innovation, excellence in operation and management, etc.) will demonstrate the unparalleled capabilities of China's plastics and rubber technologies. A series of concurrent events with experts are also curated to unlock industry trends, promote multilateral interactions and forge high-quality development of industries. Global Buyers Converge, Leading to Exceptional Industry Growth As the "Prime Platform" for plastics and rubber companies' expansion, CHINAPLAS has cultivated its roots in the international market for decades. It integrates industry resources, connects with upstream and downstream sectors of the industries, and attracts premium buyers worldwide. CHINAPLAS 2025 drew 281,206 professional visitors from over 170 countries and regions, with 68,542 attendees from overseas and Hong Kong, Macau and Taiwan region of China, accounting for 24.37% of total visitors, achieving a new milestone in internationalization. CHINAPLAS 2026 will further demonstrate its capacity to incorporate with global resources. The organizer is actively engaging in international events to establish partnerships with overseas associations and buyers from sectors including automotive, electronics & electric, packaging, etc. By leveraging CPS+ eMarketplace, CHINAPLAS's O2O strategy partner, the trade fair offers seamless "online and offline" journey-buyers can access exhibitor information and schedule on-site meetings year-round via the platform, in turn, the platform precisely matches suppliers with sourcing requests, converting online traffic to offline business exchanges, creating infinite trade opportunities. Amid ongoing uncertainties in global trade, China's plastics and rubber industries demonstrate competitive edge through "high-quality innovation". Besides seeking cost-effective products, international buyers are also sourcing advanced intelligent equipment and green materials from China, seizing market opportunities fueled by the country's robust manufacturing and innovation capabilities. By engaging with China's innovation, CHINAPLAS 2026 will serve as the core gateway for supply chain of the world's plastics and rubber industries. Embark on a Journey of Quality Industry Event CHINAPLAS will keep striving for a prosperous and sustainable future for plastics and rubber industries with innovation and green technologies - click HERE to pre-register for CHINAPLAS 2026 at USD 7.5 For more information, please click HERE. Hashtag: #CHINAPLAShttps://www.linkedin.com/showcase/chinaplas/https://x.com/chinaplashttps://www.facebook.com/Chinaplas/Wechat: CHINAPLAShttps://www.instagram.com/chinaplas_1983/The issuer is solely responsible for the content of this announcement.
A12 藝術空間
CPS
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
